Among the collection of genes, the aberrant nature of PIK3CA and MAPK1 in luminal and HER2 BCs is the key player in the oncogenicity of BC development [21,22], underscoring the potential of OT as a therapeutic agent for targeted cancer treatment. The gene discussed is MAPK1; the disease is breast cancer.